Modulators of ATP-binding cassette transporters
Compounds of the present invention, and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding. Cassette (“ABC”) transporters or fragments thereof, including. Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.
1. A method of modulating CFTR transporter activity comprising the step of contacting said ABC transporter with a compound of formula (I):
wherein independently for each occurrence:
R 1 is an optionally substituted C 1-6 aliphatic, an optionally substituted aryl, an optionally substituted heteroaryl, an optionally substituted C 3-10 cycloaliphatic, an optionally substituted 3 to 10 membered heterocycloaliphatic, carboxy, amido, amino, halo, or hydroxy, provided that at least one R 1 is an optionally substituted cycloaliphatic, an optionally substituted heterocycloaliphatic, an optionally substituted aryl, or an optionally substituted heteroaryl attached to the 1-position of the isoquinoline ring;
R 2 is hydrogen, an optionally substituted C 1-6 aliphatic, an optionally substituted C 3-6 cycloaliphatic, an optionally substituted phenyl, or an optionally substituted heteroaryl;
R 3 and R′ 3 together with the carbon atom to which they are attached form an optionally substituted C 3-7 cycloaliphatic or an optionally substituted heterocycloaliphatic;
R 4 is an optionally substituted aryl or an optionally substituted heteroaryl; and
n is 1, 2, 3, 4, 5, or 6.
2. The method of claim 1 , wherein the one R 1 attached to the 1-position of the isoquinoline ring is selected from the group consisting of
3. The method of claim 1 , wherein R 3 and R′ 3 together with the carbon atom to which they are attached form a C 3-7 cycloaliphatic.
4. The method of claim 1 , wherein R 3 and R′ 3 together with the carbon atom to which they are attached form a cyclopropyl ring.
5. The method of claim 1 , wherein R 4 is an optionally substituted phenyl.
6. The method of claim 1 , wherein R 4 is one selected from the group consisting of
7. The method of claim 1 , wherein said compound has formula II:
or a pharmaceutically acceptable salt thereof, wherein independently for each occurrence:
T is an optionally substituted C 1-2 aliphatic chain, wherein each of the carbon units is optionally and independently replaced by —CF 2 —;
R 1 ′ is hydrogen, or an optionally substituted C 1-6 aliphatic;
R D1 is attached to carbon number 3″ or 4″;
R D1 and R D2 are -Z D R 9 , wherein each Z D is independently a bond or an optionally substituted branched or straight C 1—6 aliphatic chain wherein up to two carbon units of Z D are optionally and independently replaced by —CO—, —CONR E -, —CO 2 —, —O—, —NR E CO—, —SO 2 —, —NR E -, —SO 2 —, —NR E -, or -NR E SO 2 —;
R 9 is R E , —OH, —NH 2 , —N(CH 3 ) 2 , or —N + (CH 3 ) 3 ;
or R D1 and R D2 , taken together with atoms to which they are attached, form a 3-8 membered saturated, partially unsaturated, or aromatic ring with up to 3 ring members independently selected from the group consisting of O and NR E ; and
R E is hydrogen or an optionally substituted C 1—8 aliphatic group.
8. The method of claim 7 , wherein T is selected from the group consisting of —CH 2 —and —CF 2 —.
9. The method of claim 7 , wherein R D1 is —CO 2 H attached to carbon number 3″, R D2 is H, T is —CF 2 —, and R 1 ′ is H.
10. The method of claim 7 , wherein R D1 is —CO 2 H attached to carbon number 4″, R D2 is H, T is —CF 2 —, and R 1 ′ is H.
11. The method of claim 1 , wherein the compound is selected from